Inhibition of improgan antinociception by the cannabinoid (CB)1, antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methyl-1H-pyrazole-3-carboxamide (SR141716A): Lack of obligatory role for endocannabinoids acting at CB1 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 314-322

  Hough, L B ^a   Nalwalk, J W ^b   Stadel, R ^a   Timmerman, H ^c   Leurs, R ^a   Paria, B C ^b   Wang, X ^c   Dey, S K ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANTINOCICEPTIVE AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; IMPROGAN; RECOMBINANT RECEPTOR; RIMONABANT; UNCLASSIFIED DRUG;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN STEM; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; GENE MUTATION; HUMAN; ISOTOPE LABELING; LIGAND BINDING; MOUSE; MOUSE STRAIN; NONHUMAN; NULL ALLELE; PAIN; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; TAIL FLICK TEST; WILD TYPE;

ANALGESICS; ANIMALS; BRAIN; CANNABINOIDS; CEREBRAL VENTRICLES; CIMETIDINE; ENDOCANNABINOIDS; HEAT; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; PAIN; PIPERIDINES; PYRAZOLES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 0036785529     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.036251     Document Type: Article

References (53)

1. Adams IB, Compton DR, and Martin BR (1998) Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther 284:1209-1217.
2. Bannoura MD, Nalwalk JW, Tang Y, Carlile M, Leurs R, Menge WMPB, Timmerman H, and Hough LB (1998) Absence of antinociceptive tolerance to improgan, a cimetidine analog, in rats. Brain Res 814:218-221.
3. Beitz AJ (1992) Anatomic and chemical organization of descending pain modulation systems, in Animal Pain (Short CE and Poznak AV eds) pp 31-62, Churchill Livingston, New York.
4. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, et al. (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339.
5. Compton DR, Aceto MD, Lowe J, and Martin BR (1996) In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of δ9-tetrahydrocannabinol-induced responses and apparent agonist activity. J Pharmacol Exp Ther 277:586-594.
6. Compton DR, Rice KC, De Costa BR, Razdan RK, Melvin LS, Johnson MR, and Martin BR (1993) Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther 265:218-226.
7. Crane LA and Glick SD (1979) Simple cannula for repeated intracerebral drug administration in rats. Pharmacol Biochem Behav 10:799-800.
8. Croci T, Manara L, Aureggi G, Guagnini F, Rinaldi-Carmona M, Maffrand JP, Le Fur G, Mukenge S, and Ferla G (1998) In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br J Pharmacol 125:1393-1395.
9. D'Amour FE and Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74-79.
10. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, and Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Wash DC) 258:1946-1949.
11. 2 receptor-mediated actions of anandamide in mouse brain. J Neurochem 75: 2434-2444.
12. DiMarzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, Sugiura T, and Kunos G (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature (Lond) 410:822-825.
13. Eddy NB and Leimbach D (1953) Synthetic analgesics. II. Dithienylbutenyl and dithienylbutylamines. J Pharmacol Exp Ther 107:385-393.
14. Ganellin CR (1982) Chemistry and structure-activity relationships of drugs acting at histamine receptors, in Pharmacology of Histamine Receptors (Ganellin CR and Parsons ME eds) pp 10-102, John Wright & Sons, Ltd., Bristol, UK.
15. Glick SD, Crane AM, Barker LA, and Mittag TW (1975) Effects of N-hydroxyethylpyrrolidinium methiodide, a choline analogue, on passive avoidance behaviour in mice. Neuropharmacology 14:561-564.
16. 2 receptors in the periaqueductal gray. Brain Res 588:58-66.
17. Hough LB, Nalwalk JW, Barnes WG, Warner LM, Leurs R, Menge WMPB, Timmerman H, and Wentland M (2000a) A third life for burimamide: discovery and characterization of a novel class of non-opioid analgesics derived from histamine antagonists, in New Medications for Drug Abuse (Glick SD and Maisonneuve IM eds) pp 25-40, New York Academy of Science, New York.
18. Hough LB, Nalwalk JW, Chen Y, Schuller A, Zhu Y, Zhang J, Menge WMPB, Leurs R, Timmerman H, and Pintar JE (2000b) Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res 880: 102-108.
19. Hough LB, Nalwalk JW, Leurs R, Menge WMPB, and Timmerman H (1999) Antinociceptive activity of impentamine, a histamine congener, after CNS administration. Life Sci 64:PL79-PL86.
20. Hough LB, Nalwalk JW, Leurs R, Menge WMPB, and Timmerman H (2000c) Antinociceptive activity of derivatives of improgan and burimamide. Pharmacol Biochem Behav 65:61-66.
21. 3 antagonists and derivatives. J Pharmacol Exp Ther 283:1534-1543.
22. Hough LB, Nalwalk JW, Menge WM, Leurs R, and Timmerman H (2001) Significance of GABAergic systems in the action of improgan, a non-opioid analgesic. Life Sci 68:2751-2757.
23. 2 receptors. Proc Natl Acad Sci USA 96:14136-14141.
24. Kenakin T, Morgan P, and Lutz M (1995) On the importance of the "antagonist assumption" to how receptors express themselves. Biochem Pharmacol 50:17-26.
25. Kreitzer AC and Regehr WG (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron 29:717-727.
26. 1 receptor. Eur J Pharmacol 334:R1-R2.
27. 1 receptor knockout mice. Science (Wash DC) 283:401-404.
28. Li BY, Nalwalk JW, Barker LA, Cumming P, Parsons ME, and Hough LB (1996) Characterization of the antinociceptive properties of cimetidine and a structural analog. J Pharmacol Exp Ther 276:500-508.
29. Li BY, Nalwalk JW, Finkel JM, Glick SD, and Hough LB (1997a) SKF92374, a cimetidine analog, produces mechanical and thermal antinociception in the absence of motor impairment. Analgesia 3:15-20.
30. Li BY, Nalwalk JW, and Hough LB (1997b) Effects of naltrexone and histamine antagonists on the antinociceptive activity of the cimetidine analog SKF92374 in rats. Brain Res 748:168-174.
31. 2-noradrenergic mechanism. Brain Res 559:309-314.
32. Lichtman AH and Martin BR (1997) The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. Pharmacol Biochem Behav 57:7-12.
33. Lichtman AH, Cook SA, and Martin BR (1996) Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 276:585-593.
34. Martin BR, Compton DR, Thomas BF, Prescott WR, Little PJ, Razdan RK, Johnson MR, Melvin LS, Mechoulam R, and Ward SJ (1991) Behavioral, biochemical and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 40:471-478.
35. Martin WJ, Lai NK, Patrick SL, Tsou K, and Walker JM (1993) Antinociceptive actions of cannabinoids following intraventricular administration in rats. Brain Res 629:300-304.
36. Martin WJ, Tsou K, and Walker JM (1998) Cannabinoid receptor-mediated inhibition of the rat tail-flick reflex after microinjection into the rostral ventromedial medulla. Neurosci Lett 242:33-36.
37. Meng ID, Manning BH, Martin WJ, and Fields HL (1998) An analgesia circuit activated by cannabinoids. Nature (Lond) 395:381-383.
38. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates. Academic Press, Sydney.
39. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
40. Piomelli D, Giuffrida A, Calignano A, and Rodriguez de Fonseca F (2002) The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 21:218-224.
41. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, and Caput D (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
42. Stella N, Schweitzer P, and Piomelli D (1997) A second endogenous cannabinoid that modulates long-term potentiation. Nature (Lond) 388:773-778.
43. 2 adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic. Brain Res 921:12-19.
44. Terman GW, Shavit Y, Lewis JW, Cannon JT, and Liebeskind JC (1984) Intrinsic mechanisms of pain inhibition: activation by stress. Science (Wash DC) 226:1270-1277.
45. 1 receptors. Eur J Neurosci 12:533-539.
46. Vaughan CW, McGregor IS, and Christie MJ (1999) Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. Br J Pharmacol 127:935-940.
47. Walker JM, Hohmann AG, Martin WJ, Strangman NM, Huang SM, and Tsou K (1999b) The neurobiology of cannabinoid analgesia. Life Sci 65:665-673.
48. Walker JM, Huang SM, Strangman NM, Tsou K, and Sanudo-Pena MC (1999a) Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA 96:12198-12203.
49. Welch SP, Thomas C, and Patrick GS (1995) Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 272:310-321.
50. Welch SP, Huffman JW, and Lowe J (1998) Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A. J Pharmacol Exp Ther 286:1301-1308.
51. Wilson RI and Nicoll RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (Lond) 410:588-592.
52. Zhu Y, Michalovich D, Wu H-L, Tan KB, Dytko GM, Mannan IJ, Boyce R, Alston J, Tierney LA, Li X, et al. (2001) Cloning, expression and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 59:434-441.
53. 1 receptor knockout mice. Proc Natl Acad Sci USA 96:5780-5785.